CandlesenseCandlesense
News/Companies/ELVN

ELVN News

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

ELVN

BOULDER, Colo., Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present data from its...

August 25, 2025Clinical Trials
Read more →

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVN

BOULDER, Colo., June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its underwritten public...

June 16, 2025Offering
Read more →

Jones Trading Maintains Buy on Enliven Therapeutics, Lowers Price Target to $27

ELVN

May 16, 2025
Read more →

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $40

ELVN

May 15, 2025
Read more →

Enliven Therapeutics Q1 EPS $(0.57) Misses $(0.49) Estimate

ELVN

May 14, 2025
Read more →

Enliven Therapeutics Announces Updated Data From Phase 1 ENABLE Clinical Trial Evaluating ELVN-001 In Patients With CML In Abstract Accepted For Oral Presentation At EHA 2025 Congress

ELVN

May 14, 2025
Read more →

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $39

ELVN

March 21, 2025
Read more →

Enliven Therapeutics Q4 2024 GAAP EPS $(0.46) Beats $(0.52) Estimate

ELVN

March 13, 2025
Read more →

Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

ELVN

November 15, 2024
Read more →

Jones Trading Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $36

ELVN

October 31, 2024
Read more →